Background
Michael Somogyi was born on March 7, 1883 in the village of Zsámánd in Hungary, Austria-Hungary (today Reinersdorf, part of Heiligenbrunn, Austria).
Michael Somogyi was born on March 7, 1883 in the village of Zsámánd in Hungary, Austria-Hungary (today Reinersdorf, part of Heiligenbrunn, Austria).
He graduated in chemistry from the University of Budapest in 1905 and then went to the United States.
Somogyi showed that excessive insulin makes diabetes unstable in the Chronic Somogyi rebound of which he gave his name, and first published his findings in 1938. At first, he had trouble finding suitable work, but eventually he obtained a position as an assistant of biochemistry at the Cornell University Medical College, New York where he was active until 1908. That year Somogyi returned to Budapest to become chief chemist at the municipal laboratory.
He obtained a doctorate from the University of Budapest in 1914.
The first insulin treatment of a child with diabetes in the United States of America in October 1922 was done with a preparation of insulin produced by Somogyi. In 1926, he became first chemist at the Jewish Hospital, Saint Louis.
In his first year working as a clinical chemist in Saint Louis, he introduced a method for determining reducing sugars in human blood. He took a special interest in diabetic patients and in 1938, at a meeting of the medical society in Saint Louis to the theme of “unstable, severe diabetic patients”, Somogyi first presented his theory that insulin treatment in itself might cause unstable diabetes.
In 1940 he developed a method for the determination of serum amylase in healthy and diabetic individuals.
He is also credited with devising a test for acute pancreatitis. Somogyi was active at the Jewish Hospital of Saint Louis until his retirement in 1957. He died from a stroke on 21 July 1971.